Previous 10 | Next 10 |
Gainers: Ameri Holdings (NASDAQ: AMRH ) +152% . More news on: Ameri Holdings, Inc., Westwater Resources, Inc., Genius Brands International, Inc., Stocks on the move, , Read more ...
Aduro Biotech (NASDAQ: ADRO ) has agreed to merge with privately held Chinook Therapeutics in an all-stock deal. Specifically, Aduro will acquire 100% of Chinook in exchange for 50% of its outstanding capital stock. More news on: Aduro Biotech, Inc., Healthcare stocks news, Merger & ...
BION-1301 was well-tolerated, with no serious adverse events (SAEs), treatment discontinuations or events meeting stopping criteria, across a wide range of doses Pharmacokinetics (PK) of BION-1301 were generally dose-proportional with an estimated half-life of 33 days, suggesting the...
– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy – Combined Company Will be Well-Funded With Cash Position of ~$200 Million Expected at Closing, I...
BERKELEY, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of ca...
Aduro Biotech (NASDAQ: ADRO ): Q1 GAAP EPS of -$0.09 beats by $0.05 . More news on: Aduro Biotech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
BERKELEY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of ca...
Intro Aduro (ADRO) is a biotechnology company with a focus on therapies designed to harness the body's natural immune system. Product candidates from Aduro's two primary platforms (cGAS-STING and B-select monoclonal antibody) form a pipeline of clinical and preclinical candidates that allo...
Aduro Biotech (NASDAQ: ADRO ): Q4 GAAP EPS of -$0.24 misses by $0.04 . More news on: Aduro BioTech, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BERKELEY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of ...
News, Short Squeeze, Breakout and More Instantly...
Aduro Biotech Inc. Company Name:
ADRO Stock Symbol:
NASDAQ Market:
The 15th Annual Global CSR & ESG Awards Honours 2023 Winners DA NANG, VIETNAM, Aug 30, 2023 - (ACN Newswire) - The 15th Annual Global CSR & ESG Summit & Awards ended on a high note before a full house in Da Nang, Vietnam, on August 28. Organized at the Novotel Danang Pre...
Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therap...
One-for-Five Reverse Stock Split to be Effective October 2, 2020 BERKELEY, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADURO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (ST...